Bayer’s Fundamentals Swing Upward, but the 200-Day Line Remains a Battleground

Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped 12.9% to €2.71, while reported EPS more than doubled to €2.81 from €1.32 a year earlier. Revenue came in at €13.4 billion, with organic growth of 4.1% after stripping out €886 million in negative currency effects. Yet the equity languishes at €35.93, barely above its 200-day moving average of €35.80, and sits roughly 28% below its 52-week high. The disconnect between operational progress and market valuation is stark, and it is almost entirely explained by a single factor: the unresolved US glyphosate litigation.

The operating engine is clearly humming. CEO Bill Anderson’s “Dynamic Shared Ownership” restructuring is flattening hierarchies and cutting management layers, while the company recently earned a four-star rating as a digitalization leader in the chemicals and pharmaceuticals space. Anderson has been blunt about the competitive headwinds from Germany’s energy costs — more than three times those of the Texas Gulf Coast and double China’s — but the internal overhaul is delivering measurable efficiency gains. Net debt stands at €32.5 billion, a heavy load that management is chipping away at with a symbolic dividend of just €0.11 per share for 2026.

That debt burden would feel lighter if the glyphosate cloud lifted. A proposed $7.25 billion settlement covering over 60,000 plaintiffs has passed a critical milestone: the opt-out deadline has expired, and Bayer is counting on nearly 100% participation to bring finality. The US Supreme Court is also weighing the Durnell case, which asks whether a company can be held liable under state law when the EPA has deemed the product safe. A ruling is expected by the end of the current session in June. Until that legal picture clears, the market is pricing in a substantial discount — current market capitalization of roughly €33.5 billion is barely above the net debt figure, implying an enterprise value that leaves little room for the underlying business.

Should investors sell immediately? Or is it worth buying Bayer?

On the charts, the stock is caught in a technical no-man’s-land. The €35.80 area around the 200-day line is the immediate pivot; the 50-day moving average sits at €38.39, and the 100-day at €40.58. The relative strength index at 39 is approaching oversold territory, but the momentum remains weak. Volatility over the past 30 days annualizes at 38%, high for a DAX component and a sign of frayed investor nerves. A clear break below the €33–34 support zone could open the door to the 52-week low of €25.09, though the long-term picture still shows a 34.6% gain over twelve months.

Analysts see significant upside if the legal logjam breaks. The average price target of €45.88 implies roughly 28% potential from current levels, a reward that hinges on judicial clarity. For now, Bayer presents a classic risk-reward puzzle: an improving operational core that the market refuses to fully value until the glyphosate chapter closes. Patience remains the key ingredient for investors willing to sit through the technical noise.